Voyager Therapeutics

VYGR · NASDAQ

$2.19+$0.14 (+6.83%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.05

Latest news

Press releaseAug 6, 4:01 PM ETGlobe Newswire
Voyager Reports Second Quarter 2026 Financial and Operating Results
Press releaseJul 13, 8:01 AM ETGlobe Newswire
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
NewsJul 1, 7:49 AM ETAvi Kapoor
Jim Cramer: TE Connectivity Is ‘Terrific,’ Buy This Industrial Stock
Press releaseJun 29, 8:01 AM ETGlobe Newswire
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
Press releaseJun 1, 8:00 AM ETGlobe Newswire
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease
NewsMay 14, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMay 14, 9:00 AM ETPRNewswire
A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
Press releaseMay 13, 6:01 AM ETGlobe Newswire
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026
Press releaseMay 7, 4:01 PM ETGlobe Newswire
Voyager Reports First Quarter 2026 Financial and Operating Results
Press releaseApr 27, 4:31 PM ETGlobe Newswire
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease
NewsMar 9, 4:04 PM ET
Earnings Breakdown: Voyager Therapeutics Q4
Press releaseMar 9, 4:01 PM ETGlobe Newswire
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
NewsNov 25, 12:22 PM ETVandana Singh
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline
Press releaseNov 10, 8:01 AM ETGlobe Newswire
Voyager Reports Third Quarter 2025 Financial and Operating Results
Press releaseNov 10, 8:01 AM ETGlobe Newswire
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
NewsMay 9, 5:06 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsApr 8, 2:01 PM ET
7 Analysts Assess Voyager Therapeutics: What You Need To Know
Press releaseMar 20, 9:00 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm
Press releaseMar 17, 3:03 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
NewsMar 12, 5:04 PM ET
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts
NewsMar 11, 4:02 PM ET
Voyager Therapeutics Q4 2024 GAAP EPS $(0.59) Misses $(0.38) Estimate, Sales $6.278M Miss $16.577M Estimate
Press releaseMar 11, 12:19 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
NewsMar 11, 4:32 AM ET
Earnings Scheduled For March 11, 2025
Press releaseMar 3, 2:40 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Press releaseFeb 25, 5:00 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Press releaseFeb 20, 5:40 PM ETBusiness Wire
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Press releaseFeb 19, 6:00 PM ETGlobe Newswire
Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors
Press releaseFeb 18, 5:57 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
NewsDec 2, 7:00 AM ET
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 5 Analysts
NewsNov 14, 9:00 AM ET
Voyager Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
NewsNov 11, 10:01 AM ET
Preview: Voyager Therapeutics's Earnings
NewsOct 16, 8:01 AM ET
In-Depth Examination Of 4 Analyst Recommendations For Voyager Therapeutics
NewsJul 31, 9:00 AM ET
What Analysts Are Saying About Voyager Therapeutics Stock

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Voyager Reports Second Quarter 2026 Financial and Operating Results

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

Jim Cramer: TE Connectivity Is ‘Terrific,’ Buy This Industrial Stock

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease

12 Health Care Stocks Moving In Thursday's After-Market Session

A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026

Voyager Reports First Quarter 2026 Financial and Operating Results

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease

Earnings Breakdown: Voyager Therapeutics Q4

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline

Voyager Reports Third Quarter 2025 Financial and Operating Results

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

12 Health Care Stocks Moving In Friday's After-Market Session

7 Analysts Assess Voyager Therapeutics: What You Need To Know

Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts

Voyager Therapeutics Q4 2024 GAAP EPS $(0.59) Misses $(0.38) Estimate, Sales $6.278M Miss $16.577M Estimate

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

Earnings Scheduled For March 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 5 Analysts

Voyager Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Preview: Voyager Therapeutics's Earnings

In-Depth Examination Of 4 Analyst Recommendations For Voyager Therapeutics

What Analysts Are Saying About Voyager Therapeutics Stock